BioInformant

Your Global Leader in Stem Cell Market Research

You are here: Home / Archives for news

Oscine Therapeutics to Develop Stem Cell Therapies for CNS Disorders with Support from Sana Biotechnology

By

OscineOscine Therapeutics is a newcomer to the stem cell sector, a private biotech company exploring mechanisms for treating neurodegenerative disorders through the use of replacing lost or damaged glia cells. The company is based the renowned research of Steve Goldman, M.D., Ph.D., co-director of the University of Rochester Medical Center (URMC) Center for Translational Neuromedicine.

The focus of Dr. Goldman’s research has been to manipulate the chemical signaling of pluripotent stem cell types, including embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS cells), to create healthy glia cells. [Read more…]

Minerva Biotechnologies, Interview with CEO Dr. Cynthia Bamdad

By

Minerva Biotechnologies is a regenerative medicine company specializing in stem cell therapeutics that is developing cancer immunotherapies to target 75% of solid tumors and to prevent cancer metastasis. I had the honor of interviewing Cynthia Bamdad, PhD, CEO of Minerva Biotechnologies.

In this interview, we discuss Minerva’s technology platform, product portfolio, IP strategy, and strategic goals. We also explore the significance of the company’s AlphaSTEM™ Culture System that is a simple method for inducing the naïve state in human stem cells. Enjoy. [Read more…]

6 Trends Impacting the Cord Blood Industry

By

The cord blood industry came into existence in the early 1990’s with the formation of several leading cord blood banks in the U.S., followed by the formation of cord blood banks across the globe. It has now been almost 40 years since it was first proposed that stem and progenitor cells were present in human cord blood, so the question is, what will the next 40 years hold for the cord blood banking industry?

The last few years have been marked by substantial change, as explored below. [Read more…]

ORIG3N, Producing Patient-Specific iPS Cells – Interview with Robin Smith, CEO

By

ORIG3N ORIG3N, a biotechnology start-up headquartered in Boston, is attracting global attention for several reasons. First, it has created the world’s largest blood cell repository. ORIG3N is using these blood cells to produce patient-specific induced pluripotent stem cells (iPSCs), allowing the cells to be ever-renewing and giving rise to a living database of humanity known as LifeCapsule.

Second, the company has two other business segments, called LifeProfile and LifeSystems. These business units of ORIG3N help people to better understand the links between their genes and how their minds and bodies work.

Third, ORIG3N has identified HLA Superdonor matches for 90% of the U.S. population, positioning it to be custodians of this “first of a kind asset on planet earth.”

[Read more…]

Cellerant Therapeutics Awarded 20th RMAT in U.S.

By

Cellerant Therapeutics RMATOn July 2nd, 2018, Cellerant Therapeutics was awarded a Regenerative Medicine Advanced Therapy (RMAT) designation for romyelocel-L (human myeloid progenitor cells) by the U.S. FDA. The treatment is used for the “prevention of serious bacterial and fungal infections in patients with de novo acute myeloid leukemia (AML) undergoing induction chemotherapy.”

Cellerant RMAT Designation

Romyelocel- is a universal, off-the-shelf cell therapy, because it does not require HLA matching between patient and donor. Neutropenia is a major side effect of myelosuppressive chemotherapies, including induction therapy. This can endanger patients by placing them at risk for life-threatening infections.

According to Ram Mandalam, President and CEO of Cellerant, “Receiving RMAT designation for romyelocel-L is an important milestone and recognition by the FDA of the potential of romyelocel-L to serve this unmet medical need.” [Read more…]

BioInformant's World-Class Clients